Fenwick Represents Maze Therapeutics in $115 Million Oversubscribed Series D Financing

Fenwick represented Maze Therapeutics, a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and metabolic diseases, in its completion of a $115 million Series D financing that included the conversion of issued convertible notes previously purchased by existing investors. The Series D financing was co-led by investors Frazier Life Sciences and Deep Track Capital. Janus Henderson Investors and Logos Capital also participated.

This latest funding will support the advancement of Maze’s lead programs, MZE829 and MZE782. J.P. Morgan acted as placement agent to Maze Therapeutics on the Series D financing. More information can be obtained from Maze Therapeutic’s announcement.

The Fenwick team included corporate partners Amanda Rose, Matt Rossiter and Effie Toshav, and associates James Li, Jared Leung, Melinda Banki and Ben Enos.